CEL-SCI Corporation reports on its dendritic H1N1 treatment

BioMedReports.Com, the news portal which covers Wall Street's biomedical sector and delivers financial and investment intelligence to a community of highly informed investors, has issued a special editorial report about CEL-SCI Corporation's (NYSE AMEX:CVM) presentation of data about the company's dendritic H1N1 treatment, being developed as a treatment for H1N1 hospitalized patients.

The company has attracted a great deal of interest from the biomedical investment community and while some Wall Street reporters have painted the company as little more than the latest "flu stock" play, the fact remains that both the FDA and the medical research community has taken notice of the promising new technology platform.

As indicated in the new editorial report by bio tech investment writer, Vinny Cassano, the data presented by Dr. Ken S. Rosenthal, Ph.D., Professor, Microbiology, Immunology and Biochemistry, Northeastern Ohio Universities Colleges of Medicine and Pharmacology is the only set of facts sanctioned by the company.

"There appears to be a bad-natured effort to keep negative headlines alive and to draw attention away from the facts and reports that have investors trading the stock at volume levels that haven't been seen by the company for years," writes Cassano.

The complete special report is available now at BioMedReports.Com:

http://biomedreports.com/articles/most-popular/12057-the-latest-on-cel-sci-cvm.html